0000001 001  NULL    **6;0;START              
0000001 002  -----   -----                    
0000002 010  NN1     Draxis                   Z99 
0000002 020  NN1     Health                   B2 X9.2 
0000002 030  JJ      Inc.                     I2.1 
0000002 040  VHZ     has                      Z5 A9+ A2.2 S4 
0000002 050  VVN     struck                   I3.1 E3- A1.1.1 A11.2+ A8 E2+ X3.2 A9+ 
0000002 060  AT1     a                        Z5 
0000002 070  FO      US$255-million           Z99 
0000002 080  JJ      friendly                 S1.2.1+ S7.3-/K5.2 
0000002 090  NN1     deal                     N5 Q2.2 A1.1.1 I2.2 K5.2 F3/I2.2 
0000002 100  TO      to                       Z5 
0000002 110  VBI     be                       Z5 A3+ 
0000002 120  VVN     taken                    S7.1+/A2.1[i1.2.1 M2[i1.2.1 A9+ T1.3 C1 A1.1.1 M2 S7.1- A2.1+ X2.4 S6+ S7.4+ N3 P1 M1 X2.5+ F1@ F2@ Q1.2@ B3@ 
0000002 130  RP      over                     S7.1+/A2.1[i1.2.2 M2[i1.2.2 T2- M6 
0000002 140  II      by                       Z5 
0000002 150  JJ      Jubilant                 E4.1+++ 
0000002 160  NN2     Organosys                Z99 
0000002 170  JJ      Ltd.                     I2.1 
0000002 171  ,       ,                        
0000002 180  AT1     a                        Z5 
0000002 190  RR      publicly                 A10+ 
0000002 200  VVN     traded                   I2.2 
0000002 210  NN1     company                  I2.1/S5+c S5+c G3/S5+c S3.1 K4/S5+c 
0000002 220  II      from                     Z5 
0000002 230  NP1     India                    Z2 
0000002 240  DD1     that                     Z8 Z5 
0000002 250  VBZ     is                       Z5 A3+ 
0000002 260  VVG     offering                 A9- Q2.2 
0000002 270  FO      US$6                     Z99 
0000002 280  II      per                      Z5 
0000002 290  NN1     share                    S1.1.2+ I1.1 
0000002 300  IF      for                      Z5 
0000002 310  AT      the                      Z5 
0000002 320  JJ      Canadian                 Z2 
0000002 330  NN1     drug                     B3 F3 
0000002 340  NN1     producer                 K4/S7.1+/S2mf A1.1.1/S2mf 
0000002 341  .       .                        
0000002 342  -----   -----                    
0000002 350  AT      The                      Z5 
0000002 360  NN1     deal                     N5 Q2.2 A1.1.1 I2.2 K5.2 F3/I2.2 
0000002 361  ,       ,                        
0000002 370  VVD     announced                Q2.2 
0000002 380  NPD1    Friday                   T1.3 
0000002 381  ,       ,                        
0000002 390  VBZ     is                       A3+ Z5 
0000002 400  AT      the                      Z5 
0000002 410  MD      second                   N4 
0000002 420  NN1     takeover                 S7.1+ 
0000002 430  IO      of                       Z5 
0000002 440  AT1     a                        Z5 
0000002 450  JJ      well-known               X2.2+ A11.1+ 
0000002 460  JJ      Canadian                 Z2 
0000002 470  NN1     company                  I2.1/S5+c S5+c G3/S5+c S3.1 K4/S5+c 
0000002 480  II      by                       Z5 
0000002 490  AT1     an                       Z5 
0000002 500  JJ      Indian                   Z2 
0000002 510  NN1     firm                     I2.1/S5+c 
0000002 520  CSA     as                       Z5 
0000002 530  NN2     corporations             I2.1/S5c G1.1c 
0000002 540  II      in                       Z5 
0000002 550  AT      the                      Z5 
0000002 560  JJ      fast-growing             N3.2+/A2.1/N3.8+ A5.1+/A2.1/N3.8+ 
0000002 570  JJ      Indian                   Z2 
0000002 580  NN1     economy                  I2.1 I1.3- 
0000002 590  NN1     flex                     O3 M1 
0000002 600  APPGE   their                    Z8 
0000002 610  NN1     expansion                B1[i2.2.1 N3.2+/A2.1 A4.2-/A2.1 
0000002 620  NN2     muscles                  B1[i2.2.2 B1 
0000002 630  CC      and                      Z5 
0000002 640  VV0     look                     A8 X3.4 X2.4 X7+ Z4 
0000002 650  II      beyond                   Z5 
0000002 660  NP1     Asia                     Z2 
0000002 670  TO      to                       Z5 
0000002 680  VVI     grow                     N3.2+/A2.1 A2.1+ A5.1+/A2.1 F4 
0000002 690  APPGE   their                    Z8 
0000002 700  JJ      international            M7 
0000002 710  NN1     business                 I2.1 A1.1.1 A5.1+++ 
0000002 711  .       .                        
0000002 712  -----   -----                    
0000002 720  MD      Last                     T1.1.1[i4.2.1 N4 T1.3[i3.2.1 P1/S2mf[i3.2.1 
0000002 730  NNT1    year                     T1.1.1[i4.2.2 T1.3 P1c T1.3[i3.2.2 P1/S2mf[i3.2.2 
0000002 731  ,       ,                        
0000002 740  NP1     Algoma                   Z1mf[i5.2.1 Z3c[i5.2.1 
0000002 750  NP1     Steel                    Z1mf[i5.2.2 Z3c[i5.2.2 
0000002 760  VBDZ    was                      Z5 A3+ 
0000002 770  VVN     bought                   I2.2 
0000002 780  II      by                       Z5 
0000002 790  NP1     India                    Z2 
0000002 791  GE      's                       Z5 
0000002 800  NN1     Essar                    Z99 
0000002 810  NN1     Steel                    O1.1 O2 S1.2.5+ O4.3 
0000002 820  IF      for                      Z5 
0000002 830  NNU     $1.85                    I1.2/Z99[i6.2.1 
0000002 840  NNO     billion                  I1.2/Z99[i6.2.2 N1 I1 
0000002 841  ,       ,                        
0000002 850  VVG     continuing               T2++ 
0000002 860  AT1     a                        Z5 
0000002 870  NN1     wave                     W3/M4 O4.4 Q1.1 Y1 N5 
0000002 880  IO      of                       Z5 
0000002 890  NN1     consolidation            A7+/A2.1 S5+ 
0000002 900  CST     that                     Z8 Z5 
0000002 910  VHZ     has                      Z5 A9+ A2.2 S4 
0000002 920  VVN     left                     M1 M2 A1.1.1 A1.9 A9- N5.2+ T2- 
0000002 930  AT      the                      Z5 
0000002 940  JJ      Canadian                 Z2 
0000002 950  NN1     steel                    O1.1c[i7.2.1 O1.1 O2 S1.2.5+ O4.3 
0000002 960  NN1     sector                   O1.1c[i7.2.2 A4.1 S5+ M7 N2@ 
0000002 970  II      in                       Z5 
0000002 980  JJ      foreign                  M7 
0000002 990  NN2     hands                    B1 O2 S8+ K5.2 I3.1/S2mf X9.1+/S2mf 
0000002 991  .       .                        
0000002 992  -----   -----                    
0000002 000  JJ      Indian                   Z2 
0000002 010  NN2     companies                I2.1/S5+c S5+c G3/S5+c S3.1 K4/S5+c 
0000002 020  VH0     have                     Z5 A9+ A2.2 S4 
0000002 030  RR      also                     N5++ 
0000002 040  VBN     been                     Z5 A3+ 
0000002 050  VVN@    said                     Q2.1 
0000002 060  TO      to                       Z5 
0000002 070  VBI     be                       Z5 A3+ 
0000002 080  VVG     examining                X2.4 B3 P1 
0000002 090  CSW     whether                  Z5 
0000002 100  TO      to                       Z5 
0000002 110  VVI     invest                   I1.1 
0000002 120  II      in                       Z5 
0000002 130  NN2     oilsands                 Z99 
0000002 140  NN2     properties               H1 O4.1 
0000002 150  II      in                       Z5 
0000002 160  JJ      northern                 Z2[i8.2.1 M6 
0000002 170  NP1     Alberta                  Z2[i8.2.2 
0000002 171  .       .                        
0000002 172  -----   -----                    
0000002 180  AT      The                      Z5 
0000002 190  JJ      proposed                 Q2.2/X7+ X4.1 G1.2 Q2.2/S4 
0000002 200  NN1     acquisition              A9+ 
0000002 210  IO      of                       Z5 
0000002 220  NP1     Draxis                   Z99 
0000002 221  (       (                        
0000002 230  NP1     TSX                      Z99 
0000002 231  :       :                        
0000002 240  NN1     DAX                      Z99 
0000002 241  )       )                        
0000002 250  VVZ     represents               Q1.1 A6.2+ S1.1.3 A5.4- K4 
0000002 260  AT1     a                        Z5 
0000002 270  MC      22.4                     N5[i9.3.1 N1 T1.2 T3 T1.3 N3.2 
0000002 280  NNU21   per                      N5[i9.3.2 N5[i10.2.1 
0000002 290  NNU22   cent                     N5[i9.3.3 I1 N5[i10.2.2 
0000002 300  NN1     premium                  I1.1 I1.3 A11.1+ 
0000002 310  II      over                     Z5 
0000002 320  NPD1    Thursday                 T1.3 
0000002 321  GE      's                       Z5 
0000002 330  JJ      closing                  A1.1.1 A10- T2- 
0000002 340  NN1     price                    I1.3 
0000002 350  IF      for                      Z5 
0000002 360  AT      the                      Z5 
0000002 370  NN1     company                  I2.1/S5+c S5+c G3/S5+c S3.1 K4/S5+c 
0000002 371  ,       ,                        
0000002 380  DDQ     which                    Z8 Z5 
0000002 390  VHZ     has                      A9+ Z5 A2.2 S4 
0000002 400  AT1     a                        Z5 
0000002 410  JJ      generic                  A4.2- 
0000002 420  NN1     version                  A4.1 Q2.1 
0000002 430  IO      of                       Z5 
0000002 440  NN1     Cardiolite               Z99 
0000002 441  ,       ,                        
0000002 450  AT1     a                        Z5 
0000002 460  RR      commonly                 A6.2+ 
0000002 470  JJ      used                     A1.5.1 T3+ 
0000002 480  NN1     drug                     B3 F3 
0000002 490  IF      for                      Z5 
0000002 500  JJ      nuclear                  Y1 B1 S5+% 
0000002 510  NN1     medicine                 B3 
0000002 520  NN1     imaging                  C1/Y2 X2.1/B3 
0000002 521  .       .                        
0000002 522  -----   -----                    
0000002 530  PPH1    It                       Z8 
0000002 540  VHD     had                      Z5 A9+ A2.2 S4 
0000002 550  VVN     acknowledged             Q2.2 
0000002 560  MD      last                     T1.1.1[i11.2.1 N4 
0000002 570  NNT1    month                    T1.1.1[i11.2.2 T1.3 
0000002 580  CST     that                     Z8 Z5 
0000002 590  PPH1    it                       Z8 
0000002 600  VBDZ    was                      A3+ Z5 
0000002 610  II      in                       Z5 
0000002 620  NN2     talks                    Q2.1 
0000002 630  IW      with                     Z5 
0000002 640  AT1     a                        Z5 
0000002 650  JJ      potential                A7+ 
0000002 660  NN1     buyer                    I2.2/S2mf 
0000002 661  .       .                        
0000002 662  NULL    <quote>                  
0000002 663  -----   -----                    
0000002 664  "       "                        
0000002 670  NP1     Draxis                   Z99 
0000002 680  VVZ     represents               Q1.1 A6.2+ S1.1.3 A5.4- K4 
0000002 690  AT1     a                        Z5 
0000002 700  JJ      unique                   N5--- 
0000002 710  NN1     opportunity              A1.4 
0000002 720  II      in                       Z5 
0000002 730  AT      the                      Z5 
0000002 740  NP1     North                    M6 
0000002 750  JJ      American                 Z2 
0000002 760  NN1     market                   I2.2 I2.2/H1 
0000002 761  ,       ,                        
0000002 770  VVG     offering                 A9- Q2.2 
0000002 780  JJ      Jubilant                 E4.1+++ 
0000002 790  NN1     entry                    M7 Q1.2 S7.3 M1 T2+ 
0000002 800  II      into                     Z5 
0000002 810  AT      the                      Z5 
0000002 820  JJ      attractive               O4.2+ S3.2 
0000002 821  ,       ,                        
0000002 830  VVD     regulated                A1.7+/G1.1 A1.1.1 
0000002 831  ,       ,                        
0000002 840  JJ      high                     N3.7+ N5+ A11.1+ S7.1+ A5.1+ T3- X3.2 G2.2+ E4.1+ I1.3+ F3 O4.2- O4.6+ S9 
0000002 850  NN1     growth                   N3.2+/A2.1 A5.1+/A2.1 L3 B2- 
0000002 860  CC      and                      Z5 
0000002 870  JJ      high                     N3.7+ N5+ A11.1+ S7.1+ A5.1+ T3- X3.2 G2.2+ E4.1+ I1.3+ F3 O4.2- O4.6+ S9 
0000002 880  NN1     margin                   N5 Q1.2 N5.2+ M7 A6.2- 
0000002 890  JJ      radiopharmaceutical      Z99 
0000002 900  NN1     business                 I2.1 A1.1.1 A5.1+++ 
0000002 901  ,       ,                        
0000002 902  "       "                        
0000002 903  NULL    </quote>                 
0000002 904  -----   -----                    
0000002 910  VV0     Shyam                    Z99 
0000002 920  NP1     Bhartia                  Z99 
0000002 921  ,       ,                        
0000002 930  NN1     chairman                 S7.1+/S2mf 
0000002 940  CC      and                      Z5 
0000002 950  JJ      managing                 S7.1+/S2mf[i13.2.1 S7.1+ A1.1.1 X9.2+ S7.1+/S2mf[i12.2.1 
0000002 960  NN1     director                 S7.1+/S2mf[i13.2.2 S7.1+/S2mf K4/S2mf S7.1+/S2mf[i12.2.2 
0000002 970  IO      of                       Z5 
0000002 980  AT      the                      Z5 
0000002 990  JJ      Indian                   Z2 
0000002 000  NN1     company                  I2.1/S5+c S5+c G3/S5+c S3.1 K4/S5+c 
0000002 001  ,       ,                        
0000002 010  VVD     said                     Q2.1 
0000002 020  II      in                       Z5 
0000002 030  AT1     a                        Z5 
0000002 040  NN1     release                  A1.7- A9- I2.2 K3 Q4 E6+ 
0000002 041  .       .                        
0000004 001  NULL    <quote>                  
0000004 002  -----   -----                    
0000004 003  "       "                        
0000004 010  PPH1    It                       Z8 
0000004 020  RR      also                     N5++ 
0000004 030  VVZ     enables                  S8+ 
0000004 040  JJ      Jubilant                 E4.1+++ 
0000004 050  TO      to                       Z5 
0000004 060  VVI     consolidate              A7+/A2.1 S5+ 
0000004 070  APPGE   its                      Z8 
0000004 080  NN1     position                 M6 M7 S7.1 I3.1 N4 S1.1.1 A1.1.1 K5.1% 
0000004 090  II      in                       Z5 
0000004 100  AT      the                      Z5 
0000004 110  JJ      sterile                  B4 B2-/S4 X5.2- 
0000004 120  CC      and                      Z5 
0000004 130  JJ      non-sterile              Z99 
0000004 140  NN1     contract                 I2.1 G2.1 
0000004 150  NN1     manufacturing            A1.1.1 
0000004 160  NN1     business                 I2.1 A1.1.1 A5.1+++ 
0000004 161  .       .                        
0000004 162  -----   -----                    
0000004 170  IW      With                     Z5 
0000004 180  DD1     this                     M6 Z5 Z8 
0000004 190  NN1     acquisition              A9+ 
0000004 200  JJ      Jubilant                 E4.1+++ 
0000004 210  VM      will                     T1.1.3 
0000004 220  VVI     become                   A2.1+ O4.2+ 
0000004 230  MC1     one                      N1 T3 T1.2 
0000004 240  IO      of                       Z5 
0000004 250  AT      the                      Z5 
0000004 260  JJ      leading                  S7.1+ A11.1+ A2.2 M2 A1.1.1 
0000004 270  NN2     providers                A9-/S2mf 
0000004 280  IO      of                       Z5 
0000004 290  NN1     contract                 I2.1 G2.1 
0000004 300  NN1     manufacturing            A1.1.1 
0000004 310  IO      of                       Z5 
0000004 320  JJ      small                    N3.2- N3.7- N5- T3- A11.1- S5-/I2.1 X3.2- A5.1- 
0000004 330  NN1     volume                   N3.4 N5 Q4.1 Q4.2 X3.2 
0000004 340  NN2     parenterals              B1 
0000004 350  II      to                       Z5 
0000004 360  JJ      large                    N3.2+ N5+ A11.1+ 
0000004 370  NN2     pharmaceuticals          B3 
0000004 380  CC      and                      Z5 
0000004 390  VV0     biotech                  Y1/L1 Y1/B3 
0000004 400  NN2     companies                I2.1/S5+c S5+c G3/S5+c S3.1 K4/S5+c 
0000004 410  II      in                       Z5 
0000004 420  ND1     North                    Z2[i15.2.1 M6 Z2[i14.2.1 
0000004 430  NP1     America                  Z2[i15.2.2 Z2 Z2[i14.2.2 
0000004 431  .       .                        
0000004 432  -----   -----                    
0000004 440  NN1     Draxis                   Z99 
0000004 450  VHZ     has                      A9+ Z5 A2.2 S4 
0000004 460  AT1     an                       Z5 
0000004 470  JJ      excellent                A5.1+++ 
0000004 480  JJ      regulatory               A1.7-/G1.1 
0000004 490  NN1     track                    X9.2+/T1.1.1[i16.2.1 M3 O2 K3 A4.1 X4.1 K5.1/M7 
0000004 500  NN1     record                   X9.2+/T1.1.1[i16.2.2 Q1.2 K3 T1.1.1 A5.1+++ 
0000004 501  ,       ,                        
0000004 510  IW      with                     Z5 
0000004 520  APPGE   its                      Z8 
0000004 530  NN1     management               S7.1+c 
0000004 540  CC      and                      Z5 
0000004 550  NN2     employees                I3.1/S2mf 
0000004 560  VHG     having                   A9+ Z5 A2.2 S4 
0000004 570  AT1     a                        Z5 
0000004 580  NN1     wealth                   I1.1+ 
0000004 590  IO      of                       Z5 
0000004 600  NN1     experience               X2.2+ X9.1+ I3.2 A2.1+/A3+ X3 
0000004 610  CC      and                      Z5 
0000004 620  NN1     expertise                X2.2+ X9.1+ 
0000004 630  II      in                       Z5 
0000004 640  NN2     radiopharmaceuticals     Z99 
0000004 650  CC      and                      Z5 
0000004 660  NN1     contract                 I2.1 G2.1 
0000004 670  NN1     manufacturing            A1.1.1 
0000004 671  .       .                        
0000004 672  "       "                        
0000004 673  NULL    </quote>                 
0000004 674  -----   -----                    
0000004 680  JJ      Jubilant                 E4.1+++ 
0000004 690  VBZ     is                       Z5 A3+ 
0000004 700  VVN     committed                A1.1.1 S6+ A1.7+/G2.1 
0000004 710  TO      to                       Z5 
0000004 720  VVI     grow                     N3.2+/A2.1 A2.1+ A5.1+/A2.1 F4 
0000004 730  NN1     Draxis                   Z99 
0000004 740  II      by                       Z5 
0000004 750  JJ      supporting               S8+ A1.1.1 K5.1 I1.1 A10+ 
0000004 760  NN1     management               S7.1+c 
0000004 770  CC      and                      Z5 
0000004 780  NN2     employees                I3.1/S2mf 
0000004 790  II      through                  Z5 
0000004 800  JJ      new                      T3- 
0000004 810  NN1     product                  O2 A1.1.1 A2.2 N2% 
0000004 820  NN2     launches                 M4fn M5 T2+ 
0000004 821  ,       ,                        
0000004 830  NN1     entry                    M7 Q1.2 S7.3 M1 T2+ 
0000004 840  II      into                     Z5 
0000004 850  JJ      new                      T3- 
0000004 860  NN2     markets                  I2.2 I2.2/H1 
0000004 870  CC      and                      Z5 
0000004 880  NN1     expansion                N3.2+/A2.1 A4.2-/A2.1 
0000004 890  IO      of                       Z5 
0000004 900  NN1     customer                 I2.2/S5+c[i17.2.1 I2.2/S2mf 
0000004 910  NN1     base                     I2.2/S5+c[i17.2.2 M7 T2+ A1.1.1 O1 K5.1@ B1% 
0000004 911  .       .                        
0000004 912  NULL    <quote>                  
0000004 913  -----   -----                    
0000004 914  "       "                        
0000004 920  JJ      Jubilant                 E4.1+++ 
0000004 930  NN2     Organosys                Z99 
0000004 940  VBZ     is                       A3+ Z5 
0000004 950  AT1     an                       Z5 
0000004 960  JJ      integrated               A1.8+ S5+ A2.2 N2% 
0000004 970  JJ      pharmaceutical           B3 
0000004 980  NN1     company                  I2.1/S5+c S5+c G3/S5+c S3.1 K4/S5+c 
0000004 981  ,       ,                        
0000004 990  JJ      involved                 A1.8+ A12- X5.2+ 
0000004 000  II      in                       Z5 
0000004 010  NN1     research                 X2.4 
0000004 011  ,       ,                        
0000004 020  NN1     development              A2.1+ A5.1+/A2.1 H1 
0000004 030  CC      and                      Z5 
0000004 040  NN1     manufacturing            A1.1.1 
0000004 041  .       .                        
0000004 042  -----   -----                    
0000004 050  II31    In                       N5++[i18.3.1 Z5 
0000004 060  II32    addition                 N5++[i18.3.2 
0000004 070  II33    to                       N5++[i18.3.3 Z5 
0000004 080  DA2     several                  N5 
0000004 090  NN2     locations                M7 
0000004 100  II      in                       Z5 
0000004 110  NP1     India                    Z2 
0000004 111  ,       ,                        
0000004 120  PPH1    it                       Z8 
0000004 130  VHZ     has                      A9+ Z5 A2.2 S4 
0000004 140  MC      two                      N1 T3 T1.2 
0000004 150  II      in                       Z5 
0000004 160  AT      the                      Z5 
0000004 170  NP1     United                   Z2c[i20.2.1 Z3c Z2c[i21.2.1 Z1mf[i19.2.1 Z3c[i19.2.1 
0000004 180  NP1     States                   Z2[i23.3.1 Z2[i22.3.1 Z2c[i20.2.2 Z2 Z2c[i21.2.2 Z1mf[i19.2.2 Z3c[i19.2.2 
0000004 190  II      in                       Z2[i23.3.2 Z2[i22.3.2 Z5 
0000004 200  NP1     Maryland                 Z2[i23.3.3 Z2[i22.3.3 Z2 Z3c 
0000004 210  CC      and                      Z5 
0000004 220  NP1     Washington               Z2[i24.2.1 Z3c[i24.2.1 Z2 Z1mf 
0000004 230  NN1     state                    Z2[i24.2.2 Z3c[i24.2.2 G1.1c O4.1 
0000004 231  .       .                        
0000005 001  NULL    </quote>                 
0000005 002  -----   -----                    
0000006 010  AT      The                      Z5 
0000006 020  NN1     Draxis                   Z99 
0000006 030  NN1     board                    S7.1+/S5+c[i26.3.1 S7.1+/S5+c O2 O1.1 H4 P1 K5.1 S7.1+/S5+c[i25.3.1 
0000006 040  IO      of                       S7.1+/S5+c[i26.3.2 Z5 S7.1+/S5+c[i25.3.2 
0000006 050  NN2     directors                S7.1+/S5+c[i26.3.3 S7.1+/S2mf K4/S2mf S7.1+/S5+c[i25.3.3 
0000006 060  VBZ     is                       Z5 A3+ 
0000006 070  VVG     recommending             Q2.2 
0000006 080  CST     that                     Z5 Z8 
0000006 090  NN2     shareholders             I1.1/S2mf 
0000006 100  VV0     accept                   A9+ X2.5+ S1.2.1+ S7.4+ 
0000006 110  AT      the                      Z5 
0000006 120  NN1     offer                    A9- Q2.2 I1.3- 
0000006 121  .       .                        
0000006 122  -----   -----                    
0000006 130  NN2     Analysts                 Y2/S2mf I2.1/S2mf Y1/S2mf B3/S2mf 
0000006 140  VBDR    were                     A3+ Z5 
0000006 150  JJ      quick                    N3.8+ X9.1+ L1+% 
0000006 160  TO      to                       Z5 
0000006 170  VVI     say                      Q2.1 Z4% 
0000006 180  AT      the                      Z5 
0000006 190  NN1     offering                 A9- Q2.2 
0000006 200  NN1     price                    I1.3 
0000006 210  VBDZ    was                      A3+ Z5 
0000006 220  RR      somewhat                 A13.6 
0000006 230  II      below                    Z5 
0000006 240  APPGE   their                    Z8 
0000006 250  NN1     target                   X7+ G3 K5.1 
0000006 260  NN2     prices                   I1.3 
0000006 270  IF      for                      Z5 
0000006 280  AT1     a                        Z5 
0000006 290  NN1     takeover                 S7.1+ 
0000006 300  IO      of                       Z5 
0000006 310  NP1     Draxis                   Z99 
0000006 311  ,       ,                        
0000006 320  CCB     but                      Z5 
0000006 330  DD1     that                     Z8 Z5 
0000006 340  PPHS2   they                     Z8mfn 
0000006 350  VVD     saw                      X3.4 X2.1 S1.1.1 X2.5+ X2.3+ X3 A7+ S3.2 
0000006 360  AT1     a                        Z5 
0000006 370  JJ      good                     A5.1+ G2.2+ O4.2+ A1.5.2+ N3.2+ 
0000006 380  NN1@    fit                      B2- N3.2/A5.1+ E6- 
0000006 390  II      between                  Z5 
0000006 400  AT      the                      Z5 
0000006 410  MC      two                      N1 T3 T1.2 
0000006 420  NN2     companies                I2.1/S5+c S5+c G3/S5+c S3.1 K4/S5+c 
0000006 421  .       .                        
0000006 422  -----   -----                    
0000006 430  NP1@    Desjardins               Z99 
0000006 440  NN2     Securities               G2.1 A15+ E6+ I1.1 
0000006 450  NN1     analyst                  Y2/S2mf I2.1/S2mf Y1/S2mf B3/S2mf 
0000006 460  NP1     Maher                    Z1mf[i27.2.1 Z3c[i27.2.1 
0000006 470  NP1     Yaghi                    Z1mf[i27.2.2 Z3c[i27.2.2 
0000006 480  VVD     wrote                    Q1.2 I2.1 
0000006 490  NPD1    Friday                   T1.3 
0000006 500  CST     that                     Z5 Z8 
0000006 510  DD1     that                     Z8 Z5 
0000006 511  ,       ,                        
0000006 520  II      by                       Z5 
0000006 530  APPGE   his                      Z8m 
0000006 540  NN2     calculations             N2 X2.4 
0000006 541  ,       ,                        
0000006 550  NP1     Draxis                   Z99 
0000006 560  VM      could                    A7+ 
0000006 570  VBI     be                       Z5 A3+ 
0000006 580  VVN     valued                   A11.1+ I1.3 
0000006 590  II      at                       Z5 
0000006 600  II      about                    Z5 
0000006 610  FO      US$6.60                  Z99 
0000006 620  II      per                      Z5 
0000006 630  NN1     share                    S1.1.2+ I1.1 
0000006 640  CS      if                       Z7 
0000006 650  AT      the                      Z5 
0000006 660  JJ      various                  A6.3+ 
0000006 670  NN2     parts                    N5.1- O2 M7 I3.1 S1.1.3+ K4 
0000006 680  IO      of                       Z5 
0000006 690  APPGE   its                      Z8 
0000006 700  NN1     business                 I2.1 A1.1.1 A5.1+++ 
0000006 710  VBDR    were                     Z5 A3+ 
0000006 720  VVN     considered               X2.1 X2.4 X6 
0000006 730  RR      separately               A6.1- 
0000006 731  .       .                        
0000006 732  NULL    <quote>                  
0000006 733  -----   -----                    
0000006 734  "       "                        
0000006 740  CS      While                    Z5 
0000006 750  JJ      Jubilant                 E4.1+++ 
0000006 751  GE      's                       Z5 
0000006 760  NN1     offer                    A9- Q2.2 I1.3- 
0000006 770  VBZ     is                       A3+ Z5 
0000006 780  MC      nine                     T3 N1 T1.2 T1.3 N3.2 
0000006 790  NNU21   per                      N5[i28.2.1 
0000006 800  NNU22   cent                     N5[i28.2.2 I1 
0000006 810  II      below                    Z5 
0000006 820  APPGE   our                      Z8 
0000006 830  JJ%     assessed                 X2.4/A5 P1 I1.3 
0000006 840  NN1     takeout                  Z99 
0000006 850  NN1     valuation                I1.3 
0000006 851  ,       ,                        
0000006 860  PPIS2   we                       Z8 
0000006 870  VV0     believe                  X2.1 S9% 
0000006 880  DD1     this                     M6 Z5 Z8 
0000006 890  NN1     opportunity              A1.4 
0000006 900  VVZ     provides                 A9- S6+ 
0000006 910  JJ      fair                     G2.2+ A5.1+ O4.2+ O4.3 W4 N5 
0000006 920  NN1     value                    A11.1+ I1.3 G2.2 A4.1 N1 
0000006 930  II      to                       Z5 
0000006 940  JJ      current                  T1.1.2 
0000006 950  NN2     investors                I1.1/S2mf 
0000006 960  RR      regardless               A11.1- E6+ 
0000006 961  ,       ,                        
0000006 970  VVN     given                    A9- A1.1.1 
0000006 980  AT      the                      Z5 
0000006 990  NN2     risks                    A15- A1.4 
0000006 000  JJ      involved                 A1.8+ A12- X5.2+ 
0000006 010  IW      with                     Z5 
0000006 020  AT      the                      Z5 
0000006 030  NN1     approval                 S7.4+ E2+ G1.1 
0000006 040  CC      and                      Z5 
0000006 050  NN1     launch                   M4fn M5 T2+ 
0000006 060  IO      of                       Z5 
0000006 070  JJ      generic                  A4.2- 
0000006 080  NN2     sestamibi                Z99 
0000006 081  (       (                        
0000006 090  NN1     Cardiolite               Z99 
0000006 091  )       )                        
0000006 100  II      in                       Z5 
0000006 110  AT      the                      Z5 
0000006 120  NP1     U.S.                     Z8 
0000006 130  CC      and                      Z5 
0000006 140  AT      the                      Z5 
0000006 150  JJ      potential                A7+ 
0000006 160  NN1     volatility               A2.1+ S1.2 O4.1 
0000006 170  II      in                       Z5 
0000006 180  NP1     Draxis                   Z1mf[i29.2.1 Z3c[i29.2.1 
0000006 190  NP1     Pharma                   Z1mf[i29.2.2 Z3c[i29.2.2 
0000006 191  GE      's                       Z5 
0000006 200  NN1     base                     M7 T2+ A1.1.1 O1 K5.1@ B1% 
0000006 210  NN1     business                 I2.1 A1.1.1 A5.1+++ 
0000006 220  II      considering              Z5 
0000006 230  AT1     a                        Z5 
0000006 240  JJ      possible                 A7+ 
0000006 250  NN1     phase-out                Z99 
0000006 260  II      in                       Z5 
0000006 270  MC      2009                     N1 T1.2 T3 T1.3 N3.2 
0000006 280  IO      of                       Z5 
0000006 290  NP1     Hectorol                 Z99 
0000006 291  ,       ,                        
0000006 300  RR      currently                T1.1.2 
0000006 310  AT      the                      Z5 
0000006 320  NN1     company                  I2.1/S5+c S5+c G3/S5+c S3.1 K4/S5+c 
0000006 321  GE      's                       Z5 
0000006 330  JJT     greatest                 A5.1+++ A11.1+++ N3.2+++ N5+++ X5.2+++ 
0000006 340  NN1     revenue                  G1.1/I1 I1.1+ Z3c 
0000006 350  NN1     contributor              A9-/S2mf Q4.1/S2mf 
0000006 351  .       .                        
0000006 352  "       "                        
0000006 353  NULL    </quote>                 
0000006 354  -----   -----                    
0000006 360  NN1     Hectorol                 Z99 
0000006 370  VBZ     is                       Z5 A3+ 
0000006 380  VVN     used                     T1.1.1[i30.2.1 A6.2+[i30.2.1 A1.5.1 S7.1+ 
0000006 390  TO      to                       T1.1.1[i30.2.2 A6.2+[i30.2.2 Z5 
0000006 400  VVI     treat                    S1.1.1 A9- X4.2 X2.1 B3 A1.1.1 
0000006 410  NN2     patients                 B2-/S2mf 
0000006 420  IW      with                     Z5 
0000006 430  NN1     kidney                   B2-[i31.2.1 B1 F1 
0000006 440  NN1     disease                  B2-[i31.2.2 B2- 
0000006 441  .       .                        
0000006 442  -----   -----                    
0000006 450  II      In                       Z5 
0000006 460  APPGE   its                      Z8 
0000006 470  RGT     most                     A13.2 
0000006 480  JJ      recent                   T3- 
0000006 490  JJ      financial                I1 
0000006 500  NN1     report                   Q2.2 X3.2 
0000006 501  ,       ,                        
0000006 510  NP1     Draxis                   Z99 
0000006 520  VVD     said                     Q2.1 
0000006 530  NP1     Hectorol                 Z99 
0000006 540  NN1     production               A1.1.1 A10+ K4 K3 Q4.3 
0000006 550  NN2     volumes                  N3.4 N5 Q4.1 Q4.2 X3.2 
0000006 560  II      in                       Z5 
0000006 570  MD      last                     T1.1.1[i33.2.1 N4 T1.3[i32.2.1 P1/S2mf[i32.2.1 
0000006 580  NNT1    year                     T1.1.1[i33.2.2 T1.3 P1c T1.3[i32.2.2 P1/S2mf[i32.2.2 
0000006 590  VBDR    were                     A3+ Z5 
0000006 600  NNU     $9                       Z99/H1c[i34.2.1 
0000006 610  NNO     million                  Z99/H1c[i34.2.2 N1 I1 
0000006 620  JJR     lower                    M6 N3.7-- N5-- I1.3-- A5.1-- A11.1-- E4.1-- X3.2-- G2.2-- S7.1-- 
0000006 630  CSN     than                     Z5 
0000006 640  PPHS2   they                     Z8mfn 
0000006 650  VBDR    were                     A3+ Z5 
0000006 660  II      in                       Z5 
0000006 670  MC      2006                     N1 T1.2 T3 T1.3 N3.2 
0000006 680  CC      and                      Z5 
0000006 690  RR      significantly            A11.1+ 
0000006 700  JJR     lower                    M6 N3.7-- N5-- I1.3-- A5.1-- A11.1-- E4.1-- X3.2-- G2.2-- S7.1-- 
0000006 710  CSN     than                     Z5 
0000006 720  DDQ     what                     Z8 Z5 
0000006 730  VBDZ    was                      Z5 A3+ 
0000006 740  RR      originally               T1.1.1 
0000006 750  VVN     forecasted               Q2.2/T1.1.3 X2.6+ 
0000006 760  IF      for                      Z5 
0000006 770  MC      2007                     N1 T1.2 T3 T1.3 N3.2 
0000006 771  .       .                        
0000006 772  -----   -----                    
0000006 780  NN2     Yaghi                    Z99 
0000006 790  VVD     wrote                    Q1.2 I2.1 
0000006 800  DD1     that                     Z5 Z8 
0000006 810  NN1     Draxis                   Z99 
0000006 820  VM      could                    A7+ 
0000006 830  VVI     opt                      S1.1.3-[i35.2.1 X7+ 
0000006 840  II21    out                      S1.1.3-[i35.2.2 Z5 Z5[i36.2.1 Z5[i37.2.1 A9-[i37.2.1 
0000006 850  II22    of                       Z5 Z5[i36.2.2 Z5[i37.2.2 A9-[i37.2.2 
0000006 860  APPGE   its                      Z8 
0000006 870  NN1     agreement                A6.1+ Q2.2 
0000006 880  IW      with                     Z5 
0000006 890  JJ      Jubilant                 E4.1+++ 
0000006 900  II      after                    Z5 
0000006 910  VVG     paying                   I1.2 A9- I1.1/I3.1 
0000006 920  AT1     a                        Z5 
0000006 930  NN1     break                    K1/T1.3 T2- O2 A1.4 A1.1.2 
0000006 940  NN1     fee                      I1.3 I1 
0000006 950  IO      of                       Z5 
0000006 960  FO      US$10.5                  Z99 
0000006 970  NNO     million                  N1 I1 
0000006 980  CCB     but                      Z5 
0000006 981  NULL    <quote>                  
0000006 982  -----   -----                    
0000006 983  "       "                        
0000006 990  PPIS2   we                       Z8 
0000006 000  VV0     believe                  X2.1 S9% 
0000006 010  PPH1    it                       Z8 
0000006 020  VBZ     is                       A3+ Z5 
0000006 030  JJ      unlikely                 A7- 
0000006 040  CST     that                     Z5 Z8 
0000006 050  DD1     another                  A6.1- N5++ 
0000006 060  JJ      potential                A7+ 
0000006 070  NN1     buyer                    I2.2/S2mf 
0000006 080  VM      would                    A7+ 
0000006 090  VVI     emerge                   M1 A10+ A1.1.1 
0000006 100  RR      immediately              N3.8+ T1.1.2/A11.1+ N4 
0000006 110  TO      to                       Z5 
0000006 120  VVI     provide                  A9- S6+ 
0000006 130  AT1     a                        Z5 
0000006 140  JJ      superior                 A5.1++ S7.1++ 
0000006 150  NN1     counter                  H5/I2.2 H5 N2/O2 
0000006 160  NN1     bid                      I2.2 
0000006 161  .       .                        
0000006 162  "       "                        
0000006 163  NULL    </quote>                 
0000006 164  -----   -----                    
0000006 170  NP1     Doug                     Z1mf[i38.2.1 Z3c[i38.2.1 Z1m 
0000006 180  NP1     Loe                      Z1mf[i38.2.2 Z3c[i38.2.2 
0000006 181  ,       ,                        
0000006 190  AT1     an                       Z5 
0000006 200  NN1     analyst                  Y2/S2mf I2.1/S2mf Y1/S2mf B3/S2mf 
0000006 210  IW      with                     Z5 
0000006 220  NP1     Versant                  Z99 
0000006 230  NN2     Partners                 S3.1/S2mf S3.2/S2mf S4mf 
0000006 240  JJ      Inc.                     I2.1 
0000006 241  ,       ,                        
0000006 250  VVD     said                     Q2.1 
0000006 260  CST     that                     Z8 Z5 
0000006 270  CS      while                    Z5 
0000006 280  AT      the                      Z5 
0000006 290  NN1     bid                      I2.2 
0000006 300  IF      for                      Z5 
0000006 310  NN1     Draxis                   Z99 
0000006 320  VBZ     is                       A3+ Z5 
0000006 330  JJ      attractive               O4.2+ S3.2 
0000006 331  ,       ,                        
0000006 340  PPH1    it                       Z8 
0000006 350  VBZ     is                       A3+ Z5 
0000006 360  II      below                    Z5 
0000006 370  AT      the                      Z5 
0000006 380  NN1     broker                   I2.2/S2mf S8+/S2mf 
0000006 381  GE      's                       Z5 
0000006 390  MC1     one                      N1 T3 T1.2 
0000006 400  NNT1    year                     T1.3 P1c 
0000006 410  NN1     target                   X7+ G3 K5.1 
0000006 420  IO      of                       Z5 
0000006 430  NNU     $7.50                    Z99 
0000006 440  II      per                      Z5 
0000006 450  NN1     share                    S1.1.2+ I1.1 
0000006 460  IF      for                      Z5 
0000006 470  AT      the                      Z5 
0000006 480  NP1     Toronto                  Z2 
0000006 490  NN1     company                  I2.1/S5+c S5+c G3/S5+c S3.1 K4/S5+c 
0000006 491  .       .                        
0000006 492  NULL    <quote>                  
0000006 493  -----   -----                    
0000006 494  "       "                        
0000006 500  DDQ     What                     Z8 Z5 
0000006 510  PPIS2   we                       Z8 
0000006 520  VV0     know                     X2.2+ S3.2/B1% 
0000006 530  II      about                    Z5 
0000006 540  JJ      Jubilant                 E4.1+++ 
0000006 550  II      to                       Z5 
0000006 560  DD1     this                     M6 Z5 Z8 
0000006 570  NN1     point                    Q2.1 X4.1 A5.1 A1.5.2 M7 T1.2 O4.4 O3 K5 
0000006 580  VBZ     is                       A3+ Z5 
0000006 590  CST     that                     Z8 Z5 
0000006 600  PPH1    it                       Z8 
0000006 610  VVZ     looks                    A8 X3.4 X2.4 X7+ Z4 
0000006 620  CS21    as                       Z5[i39.2.1 Z5 
0000006 630  CS22    though                   Z5[i39.2.2 Z5 
0000006 640  PPH1    it                       Z8 
0000006 641  VBZ     's                       A3+ Z5 
0000006 650  AT1     a                        Z5 
0000006 660  JJ      pharmaceutical           B3 
0000006 670  CC      and                      Z5 
0000006 680  NN2     drugs                    B3 F3 
0000006 690  NN1     development              A2.1+ A5.1+/A2.1 H1 
0000006 700  NN2     services                 S8+ S7.1- A1.1.1 S9 G3@ G2.1@ M3/M7@ 
0000006 710  CC      and                      Z5 
0000006 720  JJ      industrial               I4 
0000006 730  NN2     chemicals                O1 
0000006 740  VV0%    conglomerate             S5+ N5+ 
0000006 750  CST     that                     Z8 Z5 
0000006 760  VM      could                    A7+ 
0000006 770  RR      effectively              A5.4+ X9.2+ 
0000006 780  VVI     integrate                A1.8+ S5+ A2.2 N2% 
0000006 790  NP1     Draxis                   Z99 
0000006 791  GE      's                       Z5 
0000006 800  NN2     capabilities             X9.1+ 
0000006 810  II      in                       Z5 
0000006 820  NN1     contract                 I2.1 G2.1 
0000006 830  NN1     manufacturing            A1.1.1 
0000006 840  CC      and                      Z5 
0000006 850  JJ      nuclear                  Y1 B1 S5+% 
0000006 860  NN1     medicine                 B3 
0000006 861  ,       ,                        
0000006 862  "       "                        
0000006 863  NULL    </quote>                 
0000006 864  -----   -----                    
0000006 870  NP1@    Loe                      Z99 
0000006 880  VVD     said                     Q2.1 
0000006 881  .       .                        
0000006 882  NULL    <quote>                  
0000006 883  -----   -----                    
0000006 884  "       "                        
0000006 890  DD2     These                    Z8 Z5 
0000006 900  VBR     are                      A3+ Z5 
0000006 910  NN2     areas                    M7 A4.1 N3.6 
0000006 920  IO      of                       Z5 
0000006 930  APPGE   their                    Z8 
0000006 940  NN1     business                 I2.1 A1.1.1 A5.1+++ 
0000006 950  CST     that                     Z8 Z5 
0000006 960  VV0     seem                     A8 
0000006 970  TO      to                       Z5 
0000006 980  VBI     be                       A3+ Z5 
0000006 990  JJ      underdeveloped           A5.1- A2.1- I1.1- I4- N3.2- 
0000006 000  II      in                       A6[i40.3.1 Z5 
0000006 010  NN1     comparison               A6[i40.3.2 A6.1 
0000006 020  II      to                       A6[i40.3.3 Z5 
0000006 030  JJ      other                    A6.1- 
0000006 040  NN2     parts                    N5.1- O2 M7 I3.1 S1.1.3+ K4 
0000006 050  IO      of                       Z5 
0000006 060  APPGE   its                      Z8 
0000006 070  NN1     business                 I2.1 A1.1.1 A5.1+++ 
0000006 071  .       .                        
0000006 072  "       "                        
0000006 073  NULL    </quote>                 
0000006 074  -----   -----                    
0000006 080  II      In                       Z5 
0000006 090  VVG     trading                  I2.2 
0000006 100  RT      today                    T1.1.2 
0000006 110  II      on                       Z5 
0000006 120  AT      the                      Z5 
0000006 130  NP1     TSX                      Z99 
0000006 131  ,       ,                        
0000006 140  NP1     Draxis                   Z99 
0000006 150  NN2     shares                   N5.1- I1.1 
0000006 160  VVD     rose                     M1 N5+/A2.1 N3.2+/A2.1 S7.1+/A2.1 
0000006 170  NNU     $1.01                    Z99 
0000006 180  II      to                       Z5 
0000006 190  NNU     $5.95                    Z99 
0000006 191  ,       ,                        
0000006 200  AT1     a                        Z5 
0000006 210  NN1     gain                     A9+ N5+/A2.1 
0000006 220  IO      of                       Z5 
0000006 230  MC      20.5                     N5[i41.3.1 N1 T1.2 T3 T1.3 N3.2 
0000006 240  NNU21   per                      N5[i41.3.2 N5[i42.2.1 
0000006 250  NNU22   cent                     N5[i41.3.3 I1 N5[i42.2.2 
0000006 260  II      in                       Z5 
0000006 270  NN1     trading                  I2.2 
0000006 280  IO      of                       Z5 
0000006 290  DAR     more                     N5++ 
0000006 300  CSN     than                     Z5 
0000006 310  MC      822,000                  N1 T1.2 T3 T1.3 N3.2 
0000006 320  NN2     shares                   N5.1- I1.1 
0000006 321  .       .                        
0000009 001  NULL    **8;7;text               
